サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1798941

肝がん治療薬の世界市場

Liver Cancer Therapeutics

出版日
ページ情報
英文 287 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
肝がん治療薬の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝がん治療薬の世界市場は2030年までに94億米ドルに到達

2024年に36億米ドルと推定される肝がん治療薬の世界市場は、2024～2030年の分析期間において17.7%のCAGRで成長し、2030年には94億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである肝細胞がんは、CAGR 15.7%を記録し、分析期間終了時には33億米ドルに達すると予測されます。胆管がんセグメントの成長率は、分析期間中CAGR 20.2%と推定されます。

米国市場は9億6,790万米ドルと推定、中国はCAGR23.0％で成長すると予測

米国の肝がん治療薬市場は、2024年に9億6,790万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは23.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.3%と15.8%と予測されています。欧州では、ドイツがCAGR約14.0%で成長すると予測されています。

世界の肝がん治療薬市場- 主要動向と促進要因のまとめ

肝がんの治療環境が急速に変化しているのはなぜか？

肝がん、特に肝細胞がん（HCC）は、世界的に最も攻撃的で致命的な悪性腫瘍の1つであり、慢性肝炎感染、アルコール誘発性肝硬変、そして最近では非アルコール性脂肪性肝炎（NASH）によって、予後が著しく悪く、罹患率が上昇しています。肝がん治療薬を取り巻く環境は、単剤治療から併用療法や個別化治療戦略へのパラダイムシフトによって変化しています。歴史的にソラフェニブが支配的であった同市場は、新たな承認とパイプライン候補の波が押し寄せ、臨床診療を再構築しつつあります。分子プロファイリング、バイオマーカー同定、リアルタイムの疾患モニタリングが重視されるようになり、標的治療薬や免疫チェックポイント阻害薬へのシフトが、肝がん治療のより個別化されたアプローチを可能にしています。

規制当局が画期的治療薬の審査スケジュールを早める中、アテゾリズマブやニボルマブのような免疫腫瘍薬が、特にベバシズマブのような血管新生阻害剤との併用で人気を集めています。この二重アプローチは、腫瘍の免疫回避と血管増殖の両方に対処するように設計されており、生存利益と無増悪転帰の向上をもたらします。コンパニオン診断、循環腫瘍DNA（ctDNA）アッセイ、ゲノムシークエンシングプラットフォームに支えられ、がん専門医が個々の腫瘍シグネチャーにより効果的に治療法を適合させることができるようになり、精密医療は治療の意思決定の中心になりつつあります。

技術的進歩と治療方法は患者の転帰をどのように変えているか？

インターベンショナル腫瘍学と分子診断学における技術の進歩は、肝がん治療における治療精度を決定的に高めています。経動脈的化学塞栓療法（TACE）、ラジオ波焼灼療法（RFA）、選択的内照射療法（SIRT）などの画像誘導療法は、中期の肝細胞がんの治療や全身療法が禁忌の場合に極めて重要な役割を果たし続けています。一方、ロボット支援肝手術、3D肝モデリング、拡張現実システムは切除可能性の評価と手術成績を向上させています。これらの治療法は、早期症例、切除不能症例、再発症例を対象とした多剤併用療法において、全身療法と統合されつつあります。

次世代シークエンシング（NGS）と多分析リキッドバイオプシーの台頭により、腫瘍医はTP53、CTNNB1、TERTなど予後や治療に重要な意味を持つ遺伝子の変異を検出できるようになりました。同時に臨床研究は、Wnt/β-カテニン、PI3K/ACT/mTOR、FGFR4など、腫瘍の増殖と抵抗性を促進する分子経路を特定し、標的とすることに集中しています。ソラフェニブやレンバチニブ以外の標的キナーゼ阻害剤（レゴラフェニブ、カボザンチニブ、ラムシルマブなど）が治療抵抗性で使用され、2次治療や3次治療の選択肢を増やしています。

遺伝子治療、腫瘍浸潤リンパ球（TIL）治療、二重特異性抗体は、肝がん治療の個別化をさらに進めると期待される将来的な開発です。ナノ粒子キャリア、リポソームシステム、肝臓を標的としたプロドラッグなどのドラッグデリバリー機構の革新も、全身毒性を最小限に抑えながらバイオアベイラビリティを向上させています。これらの技術的・治療的進歩が相まって、生存への期待が再調整され、肝細胞がん治療の新たな基準が確立されつつあります。

肝がん治療薬の導入が加速している市場やセグメントは？

肝がんの世界の負担は東アジアとサハラ以南のアフリカに偏って集中しており、中国だけで世界の肝細胞がん症例の50％以上を占めています。その結果、アジア太平洋は肝がん治療薬にとって最大かつ最もダイナミックな市場であり、高い有病率、政府によるスクリーニングプログラム、急速に拡大するがん治療薬へのアクセスがその原動力となっています。日本と韓国も、強力な全国がん登録、高い診断意識、精密医療と分子診断に焦点を当てた成熟したバイオ医薬品産業により、重要な市場となっています。

北米と欧州は、強力な償還制度、先進的な腫瘍学インフラ、強固な臨床試験パイプラインの恩恵を受けており、その後に続いています。米国市場の特徴は、免疫チェックポイント阻害薬と分子誘導治療薬の高い普及率であり、FDAの好意的な承認と高コストの生物学的製剤に対する支払者負担に支えられています。欧州諸国、特にドイツと英国は、早期発見プログラムと肝疾患啓発キャンペーンに投資し、末期症状の発現を抑制しています。これらの先進地域では、遠隔モニタリングや治療アドヒアランスのためのデジタルヘルスプラットフォームの展開により、治療の継続性とフォローアップがさらに強化されています。

これとは対照的に、ラテンアメリカ、中東、東南アジアの一部では、診断の遅れ、断片的な医療システム、最新の治療薬へのアクセスの制限などが依然として残っており、十分に浸透していない市場となっています。しかし、国際NGO、官民パートナーシップ、WHOのB型肝炎・C型肝炎撲滅に向けた取り組みにより、早期介入と治療へのアクセス改善が徐々に実現しつつあります。製薬企業もまた、こうしたコストに敏感な地域に浸透させるため、差別化された価格設定、ライセンシング契約、現地製造戦略を追求しています。さらに、新興市場における肝移植プログラムの拡大により、より多くの患者集団が治癒的または緩和的治療プロトコルの対象となりつつあります。

世界の肝がん治療薬市場の成長の原動力は？

世界の肝がん治療薬市場の成長は、メタボリックシンドローム、ウイルス性肝炎、アルコール乱用の増加による肝臓がんの発生率の増加、併用療法や免疫腫瘍学的アプローチへの臨床シフトなど、いくつかの要因によって牽引されています。人口の高齢化、座りがちなライフスタイル、食生活の変化により、非ウイルス性肝細胞がんの主要な危険因子である脂肪性肝疾患やNASHが急増しています。このような疫学的な変化により、非肝硬変性肝がんの病態生理に対応したオーダーメイドの薬剤開発に対する需要が生まれています。

臨床的革新は主要な成長触媒です。標的治療薬、チェックポイント阻害薬、血管新生阻害薬（しばしば併用される）の武器の拡大は、治療の展望を大きく広げています。規制当局による早期承認、希少疾病用医薬品の指定、拡大アクセスプログラムにより、新規薬剤の商業的利用がさらに加速しています。さらに、バイオマーカー主導の薬剤開発と腫瘍微小環境研究への投資が拡大しており、個別化ワクチン、CAR-T療法、RNAベースの治療薬など、新たな治療の可能性が生まれています。

経済的・政策的インセンティブがこの勢いを強めています。高負担国の政府は、特にB型肝炎を対象に、全国的な肝がん検診とワクチン接種プログラムを実施しています。製薬企業は、合弁事業、臨床試験協力、現地R&Dハブを通じて、アジア太平洋地域でのプレゼンスを拡大しています。AIを活用した肝臓画像の読影からモバイルベースの患者エンゲージメント・プラットフォームまで、デジタルヘルス技術の統合が進んでいることも、早期診断とケアパスにおける患者の定着率向上に寄与しています。こうした医療、技術、社会・政治的促進要因が相まって、肝がん治療薬市場の堅調な成長を後押ししています。

セグメント

タイプ（肝細胞がん、胆管がん、肝芽腫、その他のタイプ）;セラピー（標的療法、放射線療法、免疫療法、化学療法）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • H3 Biomedicine Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39015

Global Liver Cancer Therapeutics Market to Reach US$9.4 Billion by 2030

The global market for Liver Cancer Therapeutics estimated at US$3.6 Billion in the year 2024, is expected to reach US$9.4 Billion by 2030, growing at a CAGR of 17.7% over the analysis period 2024-2030. Hepatocellular Carcinoma, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cholangio Carcinoma segment is estimated at 20.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$967.9 Million While China is Forecast to Grow at 23.0% CAGR

The Liver Cancer Therapeutics market in the U.S. is estimated at US$967.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 23.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Liver Cancer Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Therapeutic Landscape for Liver Cancer Rapidly Transforming?

Liver cancer, particularly hepatocellular carcinoma (HCC), represents one of the most aggressive and deadly malignancies globally, with a notably poor prognosis and rising incidence rates driven by chronic hepatitis infections, alcohol-induced cirrhosis, and increasingly, non-alcoholic steatohepatitis (NASH). The transformation of the liver cancer therapeutics landscape is being fueled by paradigm shifts from mono-therapies toward combination regimens and personalized treatment strategies. Historically dominated by sorafenib, the market has seen a wave of new approvals and pipeline candidates that are reshaping clinical practice. The shift to targeted therapies and immune checkpoint inhibitors is enabling a more tailored approach to treating liver cancer, reflecting a growing emphasis on molecular profiling, biomarker identification, and real-time disease monitoring.

With regulatory bodies accelerating review timelines for breakthrough therapies, a growing number of immuno-oncology drugs such as atezolizumab and nivolumab have gained traction, especially in combination with anti-angiogenic agents like bevacizumab. This dual approach is designed to address both tumor immune evasion and vascular proliferation, offering survival benefits and enhanced progression-free outcomes. Precision medicine is becoming central to treatment decision-making, supported by companion diagnostics, circulating tumor DNA (ctDNA) assays, and genomic sequencing platforms that enable oncologists to match therapies to individual tumor signatures more effectively.

How Are Technological Advances and Treatment Modalities Reframing Patient Outcomes?

Technological advancement in interventional oncology and molecular diagnostics is critically enhancing therapeutic precision in liver cancer care. Image-guided therapies such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and selective internal radiation therapy (SIRT) continue to play pivotal roles in treating intermediate-stage HCC or when systemic therapy is contraindicated. Meanwhile, robotic-assisted liver surgery, 3D liver modeling, and augmented reality systems are improving resectability assessment and surgical outcomes. These interventions are being increasingly integrated with systemic regimens in multimodal strategies that target early-stage, unresectable, and recurrent cases.

The rise of next-generation sequencing (NGS) and multi-analyte liquid biopsies has allowed oncologists to detect mutations in genes such as TP53, CTNNB1, and TERT, which have prognostic and therapeutic significance. Concurrently, clinical research is focused on identifying and targeting molecular pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, and FGFR4 that drive tumor growth and resistance. Targeted kinase inhibitors beyond sorafenib and lenvatinib-such as regorafenib, cabozantinib, and ramucirumab-are being deployed in treatment-refractory settings, enhancing second- and third-line therapy options.

Gene therapy, tumor-infiltrating lymphocyte (TIL) therapies, and bispecific antibodies represent future-forward developments that are expected to further personalize liver cancer treatment. Innovations in drug delivery mechanisms-including nanoparticle carriers, liposomal systems, and liver-targeted prodrugs-are also improving bioavailability while minimizing systemic toxicity. Together, these technological and therapeutic advances are recalibrating survival expectations and establishing new standards in hepatocellular carcinoma care.

Which Markets and Segments Are Accelerating Liver Cancer Therapeutics Adoption?

The global burden of liver cancer is disproportionately concentrated in East Asia and sub-Saharan Africa, with China alone accounting for over 50% of global HCC cases. Consequently, Asia-Pacific is the largest and most dynamic market for liver cancer therapeutics, driven by high prevalence, government screening programs, and rapidly expanding oncology drug access. Japan and South Korea are also significant due to strong national cancer registries, high diagnostic awareness, and a mature biopharmaceutical industry focused on precision medicine and molecular diagnostics.

North America and Europe follow closely, benefitting from strong reimbursement structures, advanced oncology infrastructure, and robust clinical trial pipelines. The U.S. market is characterized by high adoption of immune checkpoint inhibitors and molecularly guided therapies, supported by favorable FDA approvals and payer coverage for high-cost biologics. European countries, particularly Germany and the UK, are investing in early detection programs and liver disease awareness campaigns to curb late-stage presentations. The rollout of digital health platforms for remote monitoring and therapy adherence is further enhancing treatment continuity and follow-up care in these developed regions.

In contrast, Latin America, the Middle East, and parts of Southeast Asia present underpenetrated markets where late diagnosis, fragmented health systems, and limited access to modern therapeutics persist. However, international NGOs, public-private partnerships, and WHO initiatives aimed at hepatitis B and C elimination are slowly enabling earlier intervention and improved access to treatment. Pharmaceutical companies are also pursuing differential pricing, licensing agreements, and local manufacturing strategies to penetrate these cost-sensitive geographies. Additionally, with liver transplant programs expanding in emerging markets, a larger cohort of patients are now becoming eligible for curative or palliative therapeutic protocols.

What Is Fueling Growth in the Liver Cancer Therapeutics Market Globally?

The growth in the global liver cancer therapeutics market is driven by several factors, including the increasing incidence of liver cancer due to rising metabolic syndrome, viral hepatitis, and alcohol abuse, as well as the clinical shift toward combination therapies and immuno-oncology approaches. Aging populations, sedentary lifestyles, and dietary changes have led to a surge in fatty liver disease and NASH, which are major risk factors for non-viral HCC. This epidemiological shift is creating demand for tailored drug development that addresses non-cirrhotic liver cancer pathophysiology.

Clinical innovation is a major growth catalyst. The expanding armamentarium of targeted therapies, checkpoint inhibitors, and angiogenesis blockers-often used in combination-has significantly broadened the treatment landscape. Regulatory fast-tracking, orphan drug designations, and expanded access programs are further accelerating the commercial availability of novel agents. Moreover, growing investments in biomarker-driven drug development and tumor microenvironment research are generating new therapeutic possibilities, including personalized vaccines, CAR-T therapies, and RNA-based therapeutics.

Economic and policy incentives are reinforcing this momentum. Governments in high-burden countries are implementing national liver cancer screening and vaccination programs, especially for hepatitis B. Pharmaceutical companies are expanding their presence in Asia-Pacific through joint ventures, clinical trial collaborations, and local R&D hubs. The increasing integration of digital health technologies-ranging from AI-based liver imaging interpretation to mobile-based patient engagement platforms-is also contributing to early diagnosis and improved patient retention in care pathways. Together, these medical, technological, and socio-political drivers are propelling robust growth in the liver cancer therapeutics market.

SCOPE OF STUDY:

The report analyzes the Liver Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types); Therapy (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • H3 Biomedicine Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Hepatocellular Carcinoma Throws the Spotlight on Targeted Therapies
    • Expansion of Immuno-Oncology Research Pipelines Propels Growth in Checkpoint Inhibitors
    • Increased Adoption of Systemic Therapies Drives Demand for Advanced First-Line Treatment Options
    • FDA Fast-Track Approvals and Orphan Drug Designations Accelerate Market Entry for Novel Therapies
    • Growing Integration of Biomarker-Driven Approaches Expands Addressable Patient Populations
    • Clinical Advancements in Combination Therapies Strengthen Business Case for Multi-Target Regimens
    • Rise in Hepatitis B and C Prevalence Spurs Demand for Early-Stage Therapeutic Interventions
    • Expansion of Interventional Oncology Techniques Spurs Adoption of Drug-Eluting Bead Technologies
    • Increased Investment in Radiopharmaceuticals Drives Pipeline Activity in Liver Cancer Segment
    • Growing Emphasis on Genomic and Molecular Profiling Enhances Precision in Therapy Selection
    • Shift Toward Personalized Medicine Strategies Drives Interest in Companion Diagnostics
    • Rising Incidence in Asia-Pacific and Sub-Saharan Africa Expands Geographically Diverse Market Opportunities
    • Collaborations with Academic Institutions Propel Innovation in Liver Tumor Immunotherapy
    • Post-Transplant Recurrence Risk Management Sustains Demand for Adjuvant Therapeutic Options
    • Pharmaceutical R&D Consolidation Spurs Licensing and Co-Development of Liver Cancer Assets
    • Regulatory Revisions for Accelerated Approvals Drive Pipeline Commercialization
    • Increase in Health Awareness Campaigns Improves Early Diagnosis and Therapeutic Uptake
    • Advances in Liquid Biopsy Techniques Strengthen Non-Invasive Treatment Monitoring
    • Reimbursement Expansion in Developed Markets Enhances Access to Premium Therapies
    • Challenges in Treatment Response Variability Reinforce Need for Adaptive Therapy Models
    • Expansion of Cell-Based and mRNA Therapies Generates Long-Term Disruption Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cholangio Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cholangio Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cholangio Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatoblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatoblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatoblastoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • JAPAN
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CHINA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • EUROPE
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Liver Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • FRANCE
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • GERMANY
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • INDIA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Liver Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Liver Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AFRICA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030

IV. COMPETITION